PARP Inhibitors: Rich Prospects And More Deals In Store?
Executive Summary
There’s significant excitement around the potential of PARP inhibitors in the currently established indication of ovarian cancer, but the best is probably yet to come with expansion into other cancers, according to a biopharma advisory firm. This class of drugs is also expected to trigger M&A, putting the spotlight on firms like Tesaro and Clovis Oncology.
You may also be interested in...
Lynparza Partners AZ And Merck & Co Target US Breast Cancer Market
AstraZeneca and Merck & Co's strategic collaboration on the development of olaparib and other anticancers has the US breast cancer sector in its sights, with approval of a US sNDA in the indication expected in early 2018.
Tesaro Pumped As PARP Inhibitor Zejula Gets CHMP Nod
While AstraZeneca's rival drug Lynparza is catching up across the Atlantic, this likely approval for Tesaro's ovarian cancer drug will boost the US firm as it aims to make a strong start in the European market.
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.